Vicore Pharma Holding AB (VICO)

Overview

Vicore Pharma Holding AB (publ) is a clinical-stage pharmaceutical company focused on the development of novel therapies aimed at treating respiratory diseases. Originating in 2000 and operating from Stockholm, Sweden, the company has transitioned from its earlier identity as Mintage Scientific AB to its current focus on leveraging innovative drug mechanisms. Specifically, Vicore Pharma is engaging in advanced clinical trials to address the complexities of diseases such as idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. The company's strategic collaborations with Emeriti Bio AB, HaLaCore Pharma AB, and Alex Therapeutics AB underscore its commitment to expanding its therapeutic pipeline and technological capabilities. These partnerships aim to explore new molecular developments and digital solutions for managing interstitial lung diseases.

Products and Services

• C21:

An orally administered small molecule that acts as an angiotensin II type 2 receptor agonist (ATRAG), C21 is at the forefront of Vicore Pharma's clinical endeavors. Its significance lies in its progression to Phase II clinical trials for idiopathic pulmonary fibrosis (IPF) treatment and Phase I trials for pulmonary arterial hypertension. By targeting specific receptor pathways, C21 represents a novel therapeutic approach to managing these challenging respiratory conditions.

• Almee:

Almee is categorized as an investigational medical device, reaching completion in its Phase III clinical stage. Its development underscores Vicore Pharma's dedication to addressing not only the physical but also the psychological impacts of living with pulmonary fibrosis. This innovative device embodies the company's holistic approach to patient care in respiratory ailments.

• Collaborations for Molecular and Digital Development:

Through strategic alliances with Emeriti Bio AB and HaLaCore Pharma AB, Vicore Pharma is pioneering the development of new molecules based on the C21 structure and targeting the AT2 receptor. This exploratory venture is aimed at creating a robust pipeline of therapeutic options. Further extending its commitment to innovation in patient care, Vicore Pharma has also partnered with Alex Therapeutics AB. This collaboration is focused on the development of a digital application tailored to the needs of patients suffering from interstitial lung diseases, including IPF. This digital tool represents an intersection between pharmaceutical advancements and digital health, prioritizing patient engagement and management of chronic conditions.